Trends on Potential Boron-containing Drugs by Advancements in Ligand-protein Crystals Complexes.

IF 3.5 4区 医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Marvin A Soriano-Ursua, Paul Jelliss, R Ivan Cordova-Chávez, Diana Rodriguez-Vera, Yaqui Valenzuela-Schejtman, Hector Gonzalez-Espinosa, Sarai Martinez-Ceron, Eunice D Farfán-García
{"title":"Trends on Potential Boron-containing Drugs by Advancements in Ligand-protein Crystals Complexes.","authors":"Marvin A Soriano-Ursua, Paul Jelliss, R Ivan Cordova-Chávez, Diana Rodriguez-Vera, Yaqui Valenzuela-Schejtman, Hector Gonzalez-Espinosa, Sarai Martinez-Ceron, Eunice D Farfán-García","doi":"10.2174/0109298673364996250507091821","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Boron-containing compounds (BCC) are attracting attention in drug design. Certain chemical features invite the exploration of efficacious interactions on known and potential drug targets for human use.</p><p><strong>Objective: </strong>The objective of this study is to analyze the reported crystal structure studies to determine trends resulting from the inclusion of boron atoms in potential drugs.</p><p><strong>Methods: </strong>Published data in the Protein Data Bank (PDB) with at least one BCC were analyzed; both ligands and targets were analyzed to describe the inferred or reported biological activity and the potential application as a drug in the treatment of human diseases.</p><p><strong>Results: </strong>Data from the PDB indicated targets for certain infectious diseases and cancers; however, potential treatments may extend to many other human pathologies as a consequence of the careful analysis of BCCs with proteins. All classes of enzymes and receptors have been crystallized with BCCs as ligands with most complexes demonstrating interactions in the regions known as relevant to protein function.</p><p><strong>Conclusion: </strong>The number of crystallized BCC-proteins complexes is increasing, and the variability of proteins expands the possibilities of medical applications. Currently, most systems are related to cancer growth and treatment, but deeper analysis may expand BCC utility and efficacy to many other chronic and degenerative diseases.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673364996250507091821","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Boron-containing compounds (BCC) are attracting attention in drug design. Certain chemical features invite the exploration of efficacious interactions on known and potential drug targets for human use.

Objective: The objective of this study is to analyze the reported crystal structure studies to determine trends resulting from the inclusion of boron atoms in potential drugs.

Methods: Published data in the Protein Data Bank (PDB) with at least one BCC were analyzed; both ligands and targets were analyzed to describe the inferred or reported biological activity and the potential application as a drug in the treatment of human diseases.

Results: Data from the PDB indicated targets for certain infectious diseases and cancers; however, potential treatments may extend to many other human pathologies as a consequence of the careful analysis of BCCs with proteins. All classes of enzymes and receptors have been crystallized with BCCs as ligands with most complexes demonstrating interactions in the regions known as relevant to protein function.

Conclusion: The number of crystallized BCC-proteins complexes is increasing, and the variability of proteins expands the possibilities of medical applications. Currently, most systems are related to cancer growth and treatment, but deeper analysis may expand BCC utility and efficacy to many other chronic and degenerative diseases.

从配体-蛋白晶体复合物的进展看潜在含硼药物的发展趋势。
背景:含硼化合物(BCC)在药物设计中备受关注。某些化学特征要求探索已知的和潜在的药物靶点的有效相互作用,供人类使用。目的:本研究的目的是分析已报道的晶体结构研究,以确定硼原子在潜在药物中的包涵趋势。方法:对蛋白质数据库(PDB)中发表的至少有一个BCC的数据进行分析;对配体和靶标进行了分析,以描述推断或报道的生物活性以及作为药物治疗人类疾病的潜在应用。结果:来自PDB的数据显示了某些传染病和癌症的靶标;然而,潜在的治疗方法可能会扩展到许多其他人类疾病,因为仔细分析bcc与蛋白质的结果。所有类型的酶和受体都以bcc作为配体结晶,大多数复合物在已知的与蛋白质功能相关的区域显示相互作用。结论:bcc -蛋白复合物结晶数量不断增加,蛋白质的多变性扩大了医学应用的可能性。目前,大多数系统与癌症生长和治疗有关,但更深入的分析可能会将BCC的效用和疗效扩展到许多其他慢性和退行性疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current medicinal chemistry
Current medicinal chemistry 医学-生化与分子生物学
CiteScore
8.60
自引率
2.40%
发文量
468
审稿时长
3 months
期刊介绍: Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信